Somewhat Positive News Coverage Somewhat Unlikely to Impact uniQure N.V. (QURE) Stock Price
News articles about uniQure N.V. (NASDAQ:QURE) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. uniQure N.V. earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.9676424088243 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Comparing uniQure N.V. (QURE) & Its Peers (americanbankingnews.com)
- uniQure’s AMT-130 receives FDA Orphan Drug Designation in Huntington’s disease – European Biotechnology (european-biotechnology.com)
- uniQure N.V. (QURE) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington’s disease – GlobeNewswire (press release) (globenewswire.com)
- Gene Therapy for HD Gets FDA Orphan Designation (raredr.com)
uniQure N.V. (NASDAQ:QURE) opened at 11.09 on Friday. uniQure N.V. has a 52-week low of $4.72 and a 52-week high of $11.64. The firm’s market cap is $283.46 million. The firm’s 50 day moving average price is $8.99 and its 200 day moving average price is $6.94.
uniQure N.V. (NASDAQ:QURE) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.05). uniQure N.V. had a negative net margin of 289.94% and a negative return on equity of 131.27%. The company had revenue of $4.94 million during the quarter, compared to the consensus estimate of $2.92 million. Equities research analysts anticipate that uniQure N.V. will post ($3.04) EPS for the current fiscal year.
Several research analysts have weighed in on QURE shares. Chardan Capital set a $13.00 price target on uniQure N.V. and gave the stock a “buy” rating in a research report on Sunday, July 23rd. ValuEngine raised uniQure N.V. from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Zacks Investment Research lowered uniQure N.V. from a “buy” rating to a “hold” rating in a research report on Thursday, August 24th. Finally, Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $17.00 price target on shares of uniQure N.V. in a research report on Friday, June 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $12.45.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact uniQure N.V. (QURE) Stock Price” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/10/13/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-uniqure-n-v-qure-stock-price.html.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Stock Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related stocks with our FREE daily email newsletter.